OLMA · Olema Pharmaceuticals, Inc. · Exempt Offerings
$7.33
+0.57 (+8.43%)
At close · Nov 6
Return incl. dividend (before tax)
Play latest call
Q4 2024 earnings call transcript
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In addition, our condensed consolidated financial statements for the six months ended June 30, 2026 and 2025 included elsewhere in this Quarterly Report have been prepared assuming we will continue as a going concern. However, we have incurred losses and negative cash flows from operations. As a development stage company, we expect to incur significant and increasing losses until regulatory approval is granted for palazestrant or OP-3136. Regulatory approval is not guaranteed and may never be obtained. As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term.”View the 10-Q filed Aug 10, 2026
Market Cap
$609.42M
Shares
87.50M
Volume · Nov 6
1.34M
Avg daily vol (3M)
1.22M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2024-12-12 | New | Pharmaceuticals | $249,999,986 | $249,999,225 | 06b |
| 2023-09-14 | New | Pharmaceuticals | $130,000,000 | $130,000,000 | 06b |
| 2020-10-13 | New | Pharmaceuticals | $87,437,914 | $87,437,914 | 06b |
| 2020-06-23 | Amendment | Pharmaceuticals | $55,400,000 | $53,900,000 | 06b |
| 2020-03-27 | New | Pharmaceuticals | $45,000,000 | $30,000,000 | 06b |
Showing 1–5 of 5 filings
Key facts
CIK
1750284
CUSIP
68062P106
13F (30d)
71 filings
59 filers
Visit website
Investor relations